NCT02013609View on ClinicalTrials.gov

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
MDD
Interventions
DRUG

Brexpiprazole

Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally

Trial Locations (24)

10312

Staten Island

11235

Brooklyn

Jamaica

30328

Atlanta

32806

Orlando

32901

Melbourne

33016

Hialeah

33912

Fort Myers

66206

Prairie Village

77007

Houston

78229

San Antonio

78731

Austin

89102

Las Vegas

90703

Cerritos

91206

Glendale

92121

San Diego

92506

Riverside

92626

Costa Mesa

92845

Garden Grove

92868

Orange

97210

Portland

98104

Seattle

06360

Norwich

02190

Weymouth

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY